Scientist doing test in a lab, wearing a net on hair and safety glasses and a mask

In the fast-evolving world of biotechnology and pharmaceuticals, efficient supply chain management for clinical trials is critical.

The specialized transport and logistics of time - and temperature-sensitive materials, such as cell and gene therapies (CGT), require not only advanced technology but also continuous education and industry collaboration.

In this video, Michael Sweeney, QuickSTAT's Global Head of Strategy for CGT & DTP (Cell and Gene Therapy & Direct-to-Patient), shares his insights on the importance of the Global Clinical Supplies Group (GCSG) organization.

What you'll learn

  • QuickSTAT's Industry Role: How QuickSTAT operates 24/7/365 as a vital partner to ensure life-saving therapies reach patients on time and under strict temperature control.

  • Overcoming CGT Challenges: The specific strategies required to handle the complex, brand-new logistics demands of the rapidly growing cell and gene therapy market.

  • The Power of Logistics Synergy: How close collaboration between clinical trial sponsors and logistics providers eliminates handling errors and speeds up the delivery process.

Loading iFrame

Press play to get started.

Why it matters

  • Patient-Centric Success: In Direct-to-Patient (DTP) trials, any supply chain delay directly impacts a patient's treatment and well-being.

  • Protecting High-Value Cargo: Cell and gene therapies are irreplaceable; maintaining cold chain integrity prevents the catastrophic loss of invaluable medical protocols.

  • Shaping the Future of Clinical Supply: Engaging with organizations like GCSG ensures the industry stays ahead of regulatory updates and technological innovations.